SLN250117P10000
- 0.00
- 0.000.00%
Silence Therapeutics Newsroom
Top 3 Health Care Stocks That May Explode In Q4
Insider Traders Lose UK£124k As Silence Therapeutics Drops
Institutional Owners May Take Dramatic Actions as Silence Therapeutics Plc's (NASDAQ:SLN) Recent 22% Drop Adds to One-year Losses
European Equities Traded in the US as American Depositary Lower in Tuesday Trading
Chardan Capital Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $55
The Analyst Landscape: 6 Takes On Silence Therapeutics
Silence Therapeutics Is Maintained at Buy by Chardan Capital
Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK) and Silence Therapeutics (SLN)
Silence Therapeutics Price Target Maintained With a $75.00/Share by HC Wainwright & Co.
Silence Therapeutics Advances Promising SiRNA Therapy for PV
Silence Therapeutics Announces Additional Results From SANRECO Study
BMO Capital Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $67
Silence Therapeutics: Anticipated Zerlasiran Partnership and Favorable Pelacarsen CVOT Outlook Drive Buy Rating
Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference
Express News | Silence Therapeutics PLC : Jefferies Cuts Target Price to $31 From $38
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels
Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst
Silence Therapeutics Weakness After AHA Updates 'Overdone,' Says BMO Capital
SILENCE THERAPEUTICS PLC SPONSORED ADR Trading Halted, Volatility Trading Pause